Swampy
en
en
en
en
en
en
en
en
Date of Foundation
2024

Swampy

Next generation bioactive molecules

Contact

The Idea origin story

Our startup, Swampy, operates a unique platform that enables scalable exploration, prediction, validation, and enhancement of linear bioactive peptides, such as AMPs, AFPs, ACPs, and eventually Small Molecules and Natural Products. Our goal is to establish ourselves as an initial development platform, building partnerships within the pharmaceutical sector, tech industry, livestock, and plant protection. We specialize in sequence design and in vitro validation.

The Mission

Swampy deploys AI to design, synthesize and validate antimicrobials, expediting partners' evolution from sequence to solution at scale.

Clients

Pharma, Biotech, Animal Health, AgTech, Diagnostics & Material Science firms seeking novel antimicrobial, antifungal, anticancer or biofilm-active compounds for therapeutic or industrial use.

Problems we solve

Client’s problem

Drug discovery still runs on trial-and-error: <0.1 % of in-silico leads turn active. Swampy delivers a universal ML-plus-automation stack pushing hit rates >50 % across AMPs, AFPs, ACPs, small molecules and natural products—compressing years of wet-lab work into weeks and refilling global antibiotic, anticancer and antifungal pipelines.

Confirmation of problem

The problem is serious because drug-resistant infections and cancer outpace new therapies; at 0.1 % hit rates pipelines dry up, costs soar, and patients die while waiting.

Solution

Our unique solution is a combination of machine learning and automation, which drastically improves hit rates in drug discovery. The process swiftly identifies active antimicrobial, antifungal, anticancer compounds among small molecules and natural products. This revolutionary approach compresses years of

Our technologies

This solution is based on technologies

Proprietary, scalable discovery workflow + unique generative models that predict & optimize bioactive molecules end-to-end, linked to automation for fast lab validation.

How it works

Our proprietary workflow trains generative models on multi-omics data, designs candidate molecules, auto-synthesizes & robot-tests them; lab data loops back to refine models, yielding >50 % hits.

Value for the client

Pharma teams get faster, cheaper lead generation, >50 % hit rates and a de-risked pipeline—saving millions per asset and beating resistance to market first.

Market and strategy

Market size

545

mln/year

We estimate the market size for which our solution is designed in monetary terms as follows

Market share goal

0,1

% of the market

Is our goal in the next 3 years

Team

My name’s

Michel Hüller

My key role in the product

My key role is the CEO and I'm responsible for setting strategic direction, making major corporate decisions and building a high-performing team.

Team size and key members

Our team consists of Julian Hahnfeld, a soon-to-be PhD in Bioinformatics handling Database mining, and Lukas Beierle, our Deep Learning expert.

Competitors

Competitors

Key AI-drug rivals: Generate Bio, Profluent, Insilico, Recursion, Atomwise, Absci, Peptilogics, Evaxion. They use DL for proteins or small molecules but still rely on <5 % wet-lab hit rates or outsourced synthesis. No incumbent offers an end-to-end, scalable workflow coupling proprietary generative models with in-house microfluidic synthesis and HTS delivering >50 % hits.

Our Advantages

Our proprietary AI, combined with microfluidic synthesis and robotics, shortens the design-test cycle to mere weeks. With a validation over 50% for various compounds, we outpace competitors in speed and cost-effectiveness while consistently producing leads each year.

Business model

Pharma firms pay us for platform access, campaign tests, successful milestones, and royalties on licensed drugs with an Upfront/Milestones/Royalties model.

Traction

We've successfully demonstrated our concept in-silico and prepared two scholarly papers, attesting to the solid groundwork laid for our innovative approach - a testament of readiness towards gaining traction.

24 months: automated lab running; >50 % hit on 1 000 designs; three optimized AMP leads with in-vivo efficacy + PK; patents filed; two pharma MoUs; IND plan and Series-A deck ready.

Metrics

We've discovered 47,000 unique antimicrobial peptides. Following a thorough qualitative analysis for potential leads, we're now in the advanced stages of predicting and validating these sequences in-vitro.

Incorporation

Our company incorporated in

Germany

Key risks

The main risks for our startup include the complexities of bioactive molecule development, potential regulatory hurdles, reliance on technology adoption in a traditionally cautious sector, and competition from other tech-driven drug discovery platforms.

Investments

$

40000

We raised investments

Our Investors

We bootstrapped

Rising Investments

$

6000000

Currently, we are raising investments

$

12000000

Estimated pre-investment valuation of the company

Request additional information

We’re looking for a co-founders

Open positions

Article

Read

Additional information

Swampy
MVP
Date of Foundation
2024